ChemicalBook > CAS DataBase List > GDC-0623
GDC-0623
GDC-0623
- CAS No.1168091-68-6
- Chemical Name:GDC-0623
- CBNumber:CB72655407
- Molecular Formula:C16H14FIN4O3
- Formula Weight:456.21
- MOL File:1168091-68-6.mol
GDC-0623 Property
- Density 1.81±0.1 g/cm3(Predicted)
- storage temp. Store at -20°C
- solubility insoluble in H2O; ≥16.85 mg/mL in DMSO; ≥2.69 mg/mL in EtOH with ultrasonic
- form solid
- pka 14.17±0.10(Predicted)
- color Light yellow to gray
- FDA UNII HW67545I4Q
Safety
-
Symbol(GHS)
- Signal wordWarning
- Hazard statements H302-H315-H319-H335
- Precautionary statements P261-P305+P351+P338
GDC-0623 Chemical Properties,Usage,Production
- Description GDC-0623 is a potent, ATP-uncompetitive inhibitor of MEK1 (Ki = 0.13 nM in the presence of ATP). It inhibits the proliferation of A375 BRAF(V600E) and HCT116 KRAS(G13D)-mutant cancer cell lines with EC50 values of 7 and 42 nM, respectively. GDC-0623 inhibits ERK and BIM phosphorylation resulting in upregulation and stabilization of pro-apoptotic BIM protein in KRAS mutant and wild-type HCT116 cells and in KRAS mutant GW620 cells.
- Uses GDC-0623 (RG 7421) is a potent, ATP-uncompetitive inhibitor of MEK1 (Ki=0.13 nM, +ATP), and displays 6-fold weaker potency against HCT116 (KRAS (G13D), EC50=42 nM) versus A375 (BRAFV600E, EC50=7 nM).
- Definition ChEBI: GDC-0623 is a member of the class of imidazopyridines that is imidazo[1,5-a]pyridine substituted by (2-fluoro-4-iodophenyl)amino and (2-hydroxyethoxy)aminoacyl groups at positions 5 and 6. It is a potent ATP non-competitive inhibitor of MEK1 (Ki = 0.13nM) and also has efficacy against both mutant BRAF and mutant KRAS. It is in clinical development for treatment of patients with locally advanced or metastatic solid tumors. It has a role as an EC 2.7.12.2 (mitogen-activated protein kinase kinase) inhibitor, an antineoplastic agent and an apoptosis inducer. It is a substituted aniline, a member of monofluorobenzenes, an organoiodine compound, an imidazopyridine, a secondary amino compound, a hydroxamic acid ester and a primary alcohol.
-
in vivo
GDC-0623 (RG 7421) (40 mg/kg, p.o.) shows percent tumour growth inhibition (%TGI) in MiaPaCa-2 xenograft model. GDC-0623 (RG 7421) and G-573 show superior antitumour activity compared to GDC-0623 (RG 7421) in all three KRAS models[1].
- target MEK1
- IC 50 MEK1: 0.13 nM (Ki, +ATP)
- References [1] hatzivassiliou g, haling j r, chen h, et al. mechanism of mek inhibition determines efficacy in mutant kras-versus braf-driven cancers. nature, 2013, 501(7466): 232-236.
GDC-0623 Preparation Products And Raw materials
Raw materials
Preparation Products
Global(84)Suppliers
-
Supplier:
- Tel:+86-0371-86658258<br/>+8613203830695
- Email:laboratory@coreychem.com
- Country:China
- ProdList:30231
- Advantage:58
-
Supplier:
- Tel:+undefined-21-51877795
- Email:ivan@atkchemical.com
- Country:China
- ProdList:33024
- Advantage:60
-
Supplier:
- Tel:+1-2135480471<br/>+1-2135480471
- Email:sales@sarms4muscle.com
- Country:China
- ProdList:10473
- Advantage:58
-
Supplier:
- Tel:+1-708-310-1919<br/>+1-13798911105
- Email:sales@invivochem.cn
- Country:United States
- ProdList:6391
- Advantage:58
-
Supplier:
- Tel:+86-057181025280;<br/>+8617767106207
- Email:sales@molcore.com
- Country:China
- ProdList:49734
- Advantage:58
-
Supplier:
- Tel: +undefined18051384581
- Email:sales@chemhifuture.com
- Country:China
- ProdList:3135
- Advantage:58
-
Supplier:
- Tel:
- Email:support@targetmol.com
- Country:United States
- ProdList:38630
- Advantage:58
-
Supplier:
- Tel:
- Email:tp@aladdinsci.com
- Country:United States
- ProdList:57505
- Advantage:58
-
Supplier:
- Tel:571-89925085
- Email:sales@amadischem.com
- Country:China
- ProdList:131957
- Advantage:58
- Supplier: NCE Biomedical Co.,Ltd.
- Tel:4000-027-021 |24 +86-13986109188 | +86-15623472865 | +81-08033611988
- Email:
- Country:China
- ProdList:1493
- Advantage:55
1168091-68-6, GDC-0623Related Search:
- giredestrant GDC-0077 2-Propen-1-one, 1-[(3S)-4-[(7R)-7-[6-amino-4-methyl-3-(trifluoromethyl)-2-pyridinyl]-6-chloro-8-fluoro-2-[[(2S)-1-methyl-2-pyrrolidinyl]methoxy]-4-quinazolinyl]-3-methyl-1-piperazinyl]- HA-15 UNC0321 CPI-455 Maritoclax IMR-1 CHIR 99021 trihydrochloride CEP-18770 LJI308 2-((2-Chlorophenyl)(phenyl)aMino)-N-(7-(hydroxyaMino)-7-oxoheptyl)pyriMidine-5-carboxaMide AZ191 HTH-01-015 GDC-0879 4-iodo-3-nitrobenzamide VBY-825
- 合成有机化合物配体
- 抑制剂
- 细胞生物学试剂
- C16H14FIN4O3
- 化合物GDC-0623,10 MM DMSO 溶液
- 化合物GDC-0623
- MEK1抑制剂
- 5-((2-氟-4-碘苯基)氨基)-N-(2-羟基乙氧基)咪唑并[1,5-A]吡啶-6-甲酰胺
- MEK1抑制剂(GDC-0623)
- 1168091-68-6
- GDC-0623, 10 mM in DMSO
- Mitogen-activated protein kinase kinase,Apoptosis,inhibit,MEK,Inhibitor,MAP2K,MAPKK,MEK inhibitor1,GDC-0623,RG7421,GDC 0623,MEK inhibitor-1,RG-7421
- GDC-0623 (G-868)
- Imidazo[1,5-a]pyridine-6-carboxamide, 5-[(2-fluoro-4-iodophenyl)amino]-N-(2-hydroxyethoxy)-
- CS-1791
- 5-((2-FLUORO-4-IODOPHENYL)AMINO)-N-(2-HYDROXYETHOXY)IMIDAZO[1,5-A]PYRIDINE-6-CARBOXAMIDE
- G-868
- MEK inhibitor 1
- GDC-0623
- 5-(2-Fluoro-4-iodophenylamino)imidazo[1,5-a]pyridine-6-carboxylic acid N-(2-hydroxyethoxy)amide RG 7421 GDC-0623
- GDC-0623 (5-((2-Fluoro-4-Iodophenyl)amino)-N-(2-Hydroxyethoxy)imidazo[1,5-a]pyridine-6-Carboxamide)
- 5-(2-Fluoro-4-iodophenylamino)imidazo[1,5-a]pyridine-6-carboxylic acid N-(2-hydroxyethoxy)amide
- RG 7421